women. This study evaluated maternal and fetal responses to individually prescribed moderate-intensity exercise in pregnant women with chronic HTN. STUDY DESIGN: This prospective study evaluated maternal (blood pressure, heart rate, uterine artery Doppler velocimetry) and fetal (heart tracing, umbilical artery Dopplers, biophysical profile (BPP)) responses to 30 minutes of moderate-intensity (40-59% of heart rate reserve) exercise in pregnant women with chronic HTN. All were on antihypertensive medications and had no other medical comorbidities, known fetal abnormalities, or exercise contraindications. Testing occurred between 28-34 weeks. After peak exercise testing, individualized exercise prescriptions were developed. Women returned to perform a 30-minute treadmill exercise session at a heart rate within their target range. Blood pressures were measured every 5 minutes during exercise. Ultrasound before and immediately after exercise included umbilical and uterine artery Doppler velocimetry. BPPs and fetal heart tracings were recorded after exercise. Sample size calculations indicated n¼10 was sufficient to detect differences in uterine artery pulsatility index from the 50 th to 90 th percentile. Paired t-tests and Wilcoxon matched-pairs signed-ranks tests (if not normally distributed) were utilized to evaluate pre-post differences (STATA 15.1). RESULTS: Ten women completed the study. Mean age was 33 AE 4 years, BMI was 31.26 AE 6.5 . See Table for test data. Variables were normally distributed, except for S/D ratios. Uterine and umbilical artery Doppler indices (Table) did not change with exercise. Blood pressures were mildly elevated during exercise (see Figure, means AE SD). BPPs and fetal heart rate tracings were reassuring after exercise. CONCLUSION: Pregnant women with chronic hypertension tolerated moderate-intensity exercise with no adverse changes in uterine artery Doppler measures, a reflection of uterine blood flow, or fetal well-being measures. Prescribed moderate exercise did not induce extremes of maternal blood pressure. OBJECTIVE: To evaluate outcomes reported in studies on the antenatal diagnosis and management of Vasa Previa. STUDY DESIGN: MEDLINE, EMBASE, COCHRANE, PubMed and Clinicaltrials.gov were searched up to the March of 2018 for all published studies on Vasa Previa using combinations of the following MeSH and keyword terms: vasa previa, placenta previa, low lying placenta, succenturiate lobe or placenta, bilobed or bilobate placenta, velamentous insertion. Title/abstract screening and data extraction was conducted independently and in duplicate by two reviewers for all studies until total agreement for eligibility was achieved. Data extraction was also conducted in duplicate for over 60% of studies reviewed. All original human research that described maternal/obstetric and fetal/neonatal outcomes relating to pregnancies with Vasa Previa were included for analysis. RESULTS: In total, 160 published studies were examined for outcomes that pertained to pregnancies with Vasa Previa. There was a wide range of reported outcomes, many of which were reported sparingly. The most commonly reported maternal outcomes included the mode of delivery, presence of antepartum hemorrhage, time of diagnosis, rupture of membranes, and presence of known risk factors such as a low-lying placenta, succenturiate or bi-lobed placenta and (velamentous) cord insertion. The most commonly reported fetal/neonatal outcomes included fetal heart rate, gestational age at delivery, birth weight, Apgar score, presence of neonatal anemia, cord gas measurements, need for blood transfusion and death. Importantly, only three studies reported on data related to life impacts, such maternal social and emotional functioning, perceived delivery of care or resource utilization. CONCLUSION: Despite the profound effect a diagnosis of Vasa Previa has on pregnant women, families, and healthcare systems, outcomes related to life impact and resource utilization were seldom reported. There is need for development of a core outcome set, a minimum standard set of outcomes that takes ajog.org
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